Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 5.00 |
| Open | 4.94 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 4.76 - 5.05 |
| 52 Week Range | 0.79 - 10.01 |
| Volume | 2,672,343 |
| Avg. Volume | 4,272,349 |
| Market Cap | 2.994B |
| Beta (5Y Monthly) | -0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GuruFocus.com
10 Best and Worst Performing Biotechs Amid Covid-19
Here we take a look at the top ten best and worst performing biotech stocks this year Continue reading...
- GlobeNewswire
Update on HIV-BLA-PDUFA: FDA requested more information to complete a substantive review. No additional trials required. CytoDyn plans to submit the requested information and will ask for a Type A meeting with the FDA per the agency’s suggestion
Update on COVID-19: CytoDyn is planning to lock and unblind the Phase 2 COVID-19 trial data later this week. Periodic safety review by Data Safety Monitoring Committee (DSMC).
- GuruFocus.com
Biggest Year-to-Date CEO Sells
2 CEOs see price change losses since their sales Continue reading...
© 2021 Verizon Media. All rights reserved.
